[Studies on determining the mutagenicity risk of triethylenetetramine (author's transl)].
Triethylenetetramine (TETA) is the only available effective drug for the treatment of patients with Wilson's disease and with simultaneous intolerance to D-penicillamine. In the Ames-test, however both TETA and the structurally similar tetramine BE 6184 are mutagenic. The naturally occurring spermine, a closely related tetramine differing only in one additional methylene group in every carbon chain, shows no mutagenicity. TETA does not exhibit any mutagenic potency in the micronucleus-test.
D000818:Animals; D001711:Biotransformation; D002467:Cell Nucleus / Q000187:drug effects; D005029:Ethylenediamines / Q000633:toxicity*; D009153:Mutagens; D051381:Rats; D012486:Salmonella typhimurium / Q000235:genetics; D014266:Trientine / Q000378:metabolism / Q000633:toxicity*
D005029:Ethylenediamines; D009153:Mutagens; D014266:Trientine
Untersuchungen zur abschätzung des Mutagenitätsrisikos von Triethylentertramin.